Review Article
Prevalence of GenItal InfectIons In PatIents wIth dIabetes MellItus
The prevalence of genital infections in diabetes is similar in both the genders. Common mycotic genital infections found in diabetes patients are vulvovaginal infections in females and balanitis in males. [2] An Indian study identified vulvovaginal candidiasis (VVC) as the most common genital infection among women with diabetes. [3] Among the males, the incidence of Candida balanitis is reportedly higher, particularly in uncircumcised men with diabetes. [4] In a species-specific prevalence study of vaginal candidiasis among Indian women with diabetes, a vaginal swab of 36 cases was examined. The predominant Candida species isolated from study participants were Candida glabrata (39%), Candida albicans (26%), and Candida tropicalis (17%). [3] Globally, approximately 3% of uncircumcised men are affected with Candida balanoposthitis. [5] In uncircumcised males, the moist and warm space beneath the foreskin promotes the growth of the microorganisms. [4] In the US Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes 2008 survey, it was found that women and men with Type 2 DM (T2DM) had 1.9 and 2.3 times higher chances of experiencing at least one episode of vaginitis and balanitis infection, respectively, compared with women and men without diabetes. [6] C. albicans is the most common pathogen causing balanitis in men, and C. glabrata is responsible for a maximum number of genital mycosis infections in women. [7, 8] why Is there Increased rIsk of GenItal InfectIons In PatIents wIth dIabetes?
Apart from hyperglycemia and glucosuria, decreased humoral and cellular immunity, more frequent need of medical interventions, are the factors which increase the susceptibility to infections in patients with diabetes. [1, 9] Other predisposing factors contributing to genital infections include poor hygiene, topical corticosteroid use, pharmacologically induced glucosuria, pregnancy, estrogen, and oral contraceptive use. [7] The moist and warm environment of the genital area associated with hyperglycemia provides excellent growth conditions for various causative organisms, especially fungi responsible for genital infections. [8, 10] Genital infections in diabetes are often not transmitted sexually and are of mycotic origin. However, the chances of sexually transmitted infections are also considerably high among the population with T2DM. [1, 4] In recent times, pharmacologically induced glucosuria is of vital clinical concern because it increases the chances of genital infections in diabetes. SGLT2i are one such class of novel oral antidiabetic therapeutic agents that have been under close scrutiny of clinicians and researchers for its anticipated side effects of increasing chances of genital infection in diabetes. [11] In females, a glucose-inducible protein, which is structurally and functionally similar to a complement receptor CD11b/CD18, a protein found on mammalian phagocytes, is produced by C. glabrata. [3] This protein enables the fungi to adhere strongly to the vaginal epithelium and multiply, thereby making C. glabrata as most common fungus causing vaginal candidiasis. [3] [29] AmB: Amphotericin B
GenItal InfectIons and sodIuM-Glucose cotransPorter-2 InhIbItor theraPy
The SGLT2 inhibitors are responsible for pharmacologically induced urinary glucose concentration (renal glucosuria), thereby providing a favorable condition for pathogens to thrive which later results in genital infections [ Table 4 ]. [12] The mechanism of action of SGLT2 inhibitors is to prevent reabsorption of glucose by inhibiting SGLT2 protein present in proximal convoluted tubules of the kidney and facilitate its excretion in urine. [11] Currently, three SGLT2i, namely, canagliflozin, dapagliflozin, and empagliflozin, have been approved for pharmacological therapy of T2DM.
Dapagliflozin
In a meta-analysis, safety data pooled from 12 placebocontrolled trials (n = 4545) of dapagliflozin demonstrated that when administered in doses of 2.5, 5, and 10 mg/ day, the incidence of clinically diagnosed urogenital tract infection was 4.1%, 5.7%, and 4.8%, respectively [ Table 1 ], compared to 0.9% in the placebo group. [13] Vulvovaginal mycotic infections, vaginal infections, and vulvovaginal pruritus were the most common infections seen in 8.5%-10.8% women receiving dapagliflozin versus 3.4% receiving placebo. Whereas among the males, the incidence of balanitis was low but more frequent in men who received dapagliflozin (1.0%-1.2%) compared with those receiving placebo (0.1%). [13] Furthermore, it was reported that most of the genital infections documented were mild to moderate in nature and responded to the standard antimicrobial treatment. Discontinuation of dapagliflozin was rare and no clear dose-response relationship between dapagliflozin and genital infections was observed. Similarly, another literature has reported that the incidence of genital infections and their progression can be significantly reduced by maintaining perineal hygiene and standard antifungal therapy and may rarely require discontinuation of SGLT2 inhibitor therapy. [14, 15] A double-blind, parallel group, placebo-controlled study with 546 adults reported higher incidence of genital infections in the dapagliflozin group (2.5 mg, 11 patients [8%]; 5 mg, 18 [13%]; 10 mg, 12 [9%]) than in the placebo group (7 [5%] ). [16] Canagliflozin Safety study with canagliflozin showed that canagliflozin when administered as 50 mg, 100 mg, 200 mg, 300 mg daily, or 300 mg twice daily for 12 weeks resulted in vaginal Candida colonization and symptomatic vulvovaginal adverse events in females. [17] However, the symptoms were resolved with standard antifungal therapy without interruption of SGLT2 inhibitor therapy. [17] Most of the safety studies with SGLT2 inhibitors showed that symptoms of genital infection usually appeared within the first 24-26 weeks of SGLT2 inhibitor treatment. [18, 19] A single efficacy study in which patients received 100 and 300 mg of canagliflozin demonstrated early onset of genital infection symptoms in 14.5% and 14.4% patients, respectively. [20] However, pooled data from two recent randomized clinical trials with canagliflozin showed that the frequency of genital infections decreases over a period of time when patients were administered a standard 
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Study
Total study population (n)
Test dosage Incidence of genital infection
Dapagliflozin Yabe et al. [14] 16,664 Not available 2.46%-4.99% Johnsson et al. [13] 4545 2.5 mg (n=814), 5 mg (n=1145), or 10 mg (n=1193) 4.1% (2.5 mg), 5.7%(5 mg), 4.8% (10mg)
Bailey et al. [16] 546 2·5 mg (n=137), 5 mg, (n=137), or 10 mg (n=135) 8% (2·5 mg), 13% (5 mg), 9% (10 mg) Wan Seman et al. [27] 110 10 mg (n=58) 5.3% (10 mg) Kaku et al. [28] 279 1 mg (n=59), 2.5 mg (n=56), 5 mg (n=58), or 10 mg (n=52) 0% (1 mg), 1.7% (2.5 mg), 1.7% (5 mg), 0% (10 mg) Canagliflozin
Prasanna Kumar et al. [22] 9439 100 mg (n=3092) or 300 mg (n=3085)
3.4% (100 mg), 4.5% (300 mg)
Bode et al. [20] 714 100 mg (n=241) or 300 mg (n=236) 14.5% (100 mg), 14.45% (300 mg) Empagliflozin
Zinman et al. [24] 6563 10 mg (n=2345) or 25 mg (n=2342) 6.5% (10 mg), 6.3% (25 mg) Kim et al. [23] 2477 10 mg or 25 mg 4.2% (10 mg), 3.6% (25 mg) SGLT2: Sodium-glucose cotransporter-2 treatment dose of 100-300 mg/day. [20, 21] A high incidence of genital infections was reported within first 3 months of initiating therapy (females: canagliflozin 100 mg/day: 9.2%, canagliflozin 300 mg/day: 8.3%, control: 0.6%; males: canagliflozin 100 mg/day: 3.5%, canagliflozin 300 mg/day: 3.5%, control: 0.2%), which decreased gradually and was lowest after 21 months of therapy (females: canagliflozin 100 mg/day: 0.4%, canagliflozin 300 mg/day: 1.6%, control: 0.5%; males: canagliflozin 100 mg/day: 0.3%, canagliflozin 300 mg/day: 0.4%, control: 0.4%). [21] Data from the Indian subset of an efficacy and safety study of canagliflozin in T2DM patient (n = 1038) reported the incidence of genital infection only in canagliflozin group (1.2% [100 mg, n = 4] and 3.2% [300 mg, n = 11]) [ Table 1 ], and no episode of genital infection was reported in placebo group. [22] Empagliflozin Safety data pooled from four randomized, placebo-controlled Phase III trials (n = 2477 patients) showed that patients on empagliflozin therapy had a higher incidence (empagliflozin 10 mg: 4.2%, empagliflozin 25 mg: 3.6%) of genital infections as compared with patients on placebo therapy (0.7%). [23] In addition, genital infections were more common in women (placebo: 1%, empagliflozin 10 mg: 6.3%, and empagliflozin 25 mg: 7.0%) than in men (placebo: 0.5%, empagliflozin 10 mg: 2.6%, and empagliflozin 25 mg: 1.1%). Most of the patients reporting these events had only one episode of genital infections, and only a few of them (empagliflozin 10 mg: 0.1%, empagliflozin 25 mg: 0.2%) discontinued empagliflozin therapy due to these events. [23] Another safety study with empagliflozin also reported a higher incidence of genital infection in empagliflozin group (6.4%, n = 4687) as compared with the placebo group (1.8%, n = 2333) [ Table 1 ]. [24] 
GenItal InfectIon In sPecIal PoPulatIons on sodIuM-Glucose cotransPorter-2 InhIbItor theraPy
Certain special populations including postmenopausal women and uncircumcised men with diabetes are anticipated to experience genital infections to a greater extent than other individuals. The prevalence of genital infections in postmenopausal diabetic women on SGLT2i therapy is still not clearly established due to scarcity of evidence. [25] However, it has been hypothesized that hormonal changes during and postmenopause are related to diminished immunity in the female reproductive tract, which increases the chances of having genital infections. [25] Similarly, circumcision in men is associated with maintenance of genital hygiene which is indirectly related to lower incidence of genital infection. [8] Pooled data from eight studies (n = 9439) with longer mean exposure (68 weeks of canagliflozin, 64 weeks of placebo) showed that the rate of male genital mycotic infection was more common in uncircumcised men (11%) than in circumcised men (3%). [26] A safety study which included 110 participants compared the safety of dapagliflozin with sulfonylurea during the fasting month of Ramadan and reported a lower risk of genital infections in the dapagliflozin group (5.3%) as compared with sulfonylurea group. [27] This possible reduction in the incidence of genital infection, particularly in males, could be related to higher rate of circumcision among the cases included in the Ramadan study.
Even though the literature is scarce, a few researchers claim that Japanese men with diabetes exhibit a considerably lower incidence of genital infections due to the maintenance of better hygiene. For instance, in an efficacy and safety study of dapagliflozin as a monotherapy in Japanese patients with T2DM (n = 279) who had inadequate glycemic control, only two patients (one case each in the dapagliflozin 2.5-and 5-mg groups) reported signs, symptoms, and other reports suggestive of genital infection. [28] 
PreventIon of GenItal InfectIon In PatIents wIth dIabetes on sodIuM-Glucose cotransPorter-2 InhIbItor theraPy
Clinical evidence suggests that SGLT2 inhibitor induces glucosuria which leads to preferable conditions for pathogens to thrive and grow thereby resulting in genital infection. Proper counseling regarding pros and cons of SGLT2i therapy is essential for naïve patients for decreasing the risk of genitourinary infection [ Figure 1 ].
Perineal hygiene
Patient education about perineal hygiene should be taken as a preemptive measure for all the diabetic patients irrespective of the antidiabetic therapy. This should include washing of genital organs followed by urination or defecation, routine hygienic wipes or sprays, women should be advised to wash from front-to-back, uncircumcised males should retract the prepuce before wash, use clean water for washing or mild soap if required, alcohol-based disinfectant should not be used for washing. [13] 
treatMent of GenItal InfectIon In PatIents on sodIuM-Glucose cotransPorter-2 InhIbItor theraPy
Although the chances of genital infections in patients with T2DM are considerably high, a better prognosis can be achieved with prompt treatment. [9, 10] Safety and efficacy studies with SGLT2 inhibitors have shown that genital infections reported in the study population are often mild to moderate in severity and respond well to conventional therapy. [18, 19] As per the Infectious Diseases Society of America, 2016, clinical practice guidelines for the management of candidiasis for the treatment of uncomplicated Candida vulvovaginitis, topical antifungal agents are recommended [ Tables 2 and 3 ]. Whereas, for patients who have a recurrent infection, oral fluconazole 150 mg weekly for 6 months is recommended. [29] Recommendations by the Society of Obstetricians and Gynaecologists of Canada, 2015, recommended that symptomatic VVC should be treated with topical azoles. The topical antifungal agents comprise primarily of imidazoles such as miconazole and clotrimazole. [10] In addition, for effective management of recurrent VVC, initial therapy should be followed by weekly oral fluconazole for up to 6 months. [30, 31] 
treatMent of Candida balanItIs
Balanitis is usually associated with poor hygiene and hence frequent normal saline washes are recommended. Recommended regimen is clotrimazole cream 1% twice a day for 10 days. Miconazole cream 2% is also an alternative to clotrimazole cream. Relief is almost immediate, but treatment is to be continued for 10 days. Addition of topical steroids is not usually recommended in mild cases but where there is marked inflammation 1% hydrocortisone is used along with topical imidazoles. Topical therapy is usually sufficient in most of the cases of Candida balanitis. [32] contInuatIon of sodIuM-Glucose cotransPorter-2 InhIbItor theraPy after an ePIsode of GenItal InfectIon
The majority of the clinical trials with SGLT2 inhibitors have reported that discontinuation of therapy during an episode of genital infection is not related to better prognosis. [15] [16] [17] [18] Genital infections in such patients are mild to moderate in nature which respond well to standard treatment, and do not require discontinuation of SGLT2 therapy. [15] [16] [17] [18] suMMary Drug-induced glucosuria, decreased immune response, and altered microflora of the genital region are the main factors responsible for high incidence of genital infections in cases with diabetes. The anticipated association of SGLT2 inhibitors and increased risk of genital infection is a major cause of concern for diabetologists.
Genital infections following SGLT2 inhibitor therapy are mild to moderate in nature which respond well to the conventional therapy. Adequate counseling might help in preventing the risk of genital infections in patients with diabetes on SGLT2i treatment.
